Hepatocellular Carcinoma - Pipeline Review, H2 2017

Publisher Name :
Date: 30-Nov-2017
No. of pages: 1120
Inquire Before Buying

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 79, 51, 3, 72, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 7, 1, 26 and 2 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)


Reasons to buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Hepatocellular Carcinoma - Pipeline Review, H2 2017

Table of Contents

Table of Contents 2
Introduction 8
Hepatocellular Carcinoma - Overview 9
Hepatocellular Carcinoma - Therapeutics Development 10
Hepatocellular Carcinoma - Therapeutics Assessment 42
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 64
Hepatocellular Carcinoma - Drug Profiles 125
Hepatocellular Carcinoma - Dormant Projects 1068
Hepatocellular Carcinoma - Discontinued Products 1076
Hepatocellular Carcinoma - Product Development Milestones 1079
Appendix 1092

List of Tables

Number of Products under Development for Hepatocellular Carcinoma, H2 2017 37
Number of Products under Development by Companies, H2 2017 39
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 40
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 41
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 42
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 43
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 44
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 45
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 46
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 47
Number of Products under Development by Universities/Institutes, H2 2017 48
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 50
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 51
Products under Development by Companies, H2 2017 52
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 53
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 54
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 55
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 56
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 57
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 58
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 59
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 60
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 61
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 62
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 63
Products under Development by Companies, H2 2017 (Contd..12), H2 2017 64
Products under Development by Companies, H2 2017 (Contd..13), H2 2017 65
Products under Development by Universities/Institutes, H2 2017 66
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 67
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 68
Number of Products by Stage and Target, H2 2017 70
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 71
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 72
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 73
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 74
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 75
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 76
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 77
Number of Products by Stage and Mechanism of Action, H2 2017 79
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 80
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 81
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 82
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 83
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 84
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 85
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 86
Number of Products by Stage and Route of Administration, H2 2017 88
Number of Products by Stage and Molecule Type, H2 2017 90
Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H2 2017 91
Hepatocellular Carcinoma - Pipeline by Abivax SA, H2 2017 91
Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H2 2017 92
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2017 92
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2017 93
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2017 93
Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2017 94
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2017 94
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2017 94
Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 95
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2017 95
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017 96
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2017 96
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2017 97
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017 97
Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017 98
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2017 98
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2017 99
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 99
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2017 99
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H2 2017 100
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2017 101
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2017 101
Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H2 2017 101
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2017 102
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2017 102
Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2017 103
Hepatocellular Carcinoma - Pipeline by Cellivery Therapeutics Inc, H2 2017 103
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2017 104
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2017 104
Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2017 104
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 105
Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 105
Hepatocellular Carcinoma - Pipeline by Curevac AG, H2 2017 106
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2017 106
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2017 107
Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H2 2017 107
Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017 107
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2017 108
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H2 2017 109
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2017 109
Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H2 2017 110
Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2017 110
Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H2 2017 110
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2017 111
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 111
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2017 112
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2017 112
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2017 112
Hepatocellular Carcinoma - Pipeline by Genentech Inc, H2 2017 113
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2017 113
Hepatocellular Carcinoma - Pipeline by Genosco Inc, H2 2017 114
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2017 114
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2017 115
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2017 115
Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2017 116
Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2017 116
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2017 117
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2017 117
Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H2 2017 117
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2017 118
Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2017 118
Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2017 119
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2017 119
Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2017 119
Hepatocellular Carcinoma - Pipeline by Incyte Corp, H2 2017 120
Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 120
Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2017 121
Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2017 121
Hepatocellular Carcinoma - Pipeline by Ipsen SA, H2 2017 122
Hepatocellular Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 122
Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2017 123
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2017 123
Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2017 123
Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2017 124
Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2017 124
Hepatocellular Carcinoma - Pipeline by Kowa Co Ltd, H2 2017 125
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2017 125
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 126
Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2017 126
Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2017 127
Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2017 127
Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2017 128
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2017 128
Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 129
Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2017 129
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 129
Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2017 130
Hepatocellular Carcinoma - Pipeline by Molecular Templates Inc, H2 2017 130
Hepatocellular Carcinoma - Pipeline by MTG Biotherapeutics Inc, H2 2017 130
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2017 131
Hepatocellular Carcinoma - Pipeline by NeuroVive Pharmaceutical AB, H2 2017 131
Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2017 132
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2017 132
Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2017 133
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2017 133
Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2017 134
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2017 134
Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2017 135
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 135
Hepatocellular Carcinoma - Pipeline by OSE Immunotherapeutics, H2 2017 136
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2017 136
Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2017 136
Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017 137
Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2017 138
Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2017 138
Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2017 139
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2017 139
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH (Inactive), H2 2017 139
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 140
Hepatocellular Carcinoma - Pipeline by Q BioMed Inc, H2 2017 140
Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2017 141
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2017 141
Hepatocellular Carcinoma - Pipeline by Samumed LLC, H2 2017 141
Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2017 142
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2017 142
Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2017 143
Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H2 2017 143
Hepatocellular Carcinoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 144
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2017 144
Hepatocellular Carcinoma - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 145
Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2017 145
Hepatocellular Carcinoma - Pipeline by tella Inc, H2 2017 145
Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 146
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2017 146
Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2017 146
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 147
Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2017 147
Hepatocellular Carcinoma - Pipeline by Twoxar Inc, H2 2017 148
Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2017 148
Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2017 148
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2017 149
Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2017 149
Hepatocellular Carcinoma - Pipeline by VG Life Sciences Inc, H2 2017 149
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2017 150
Hepatocellular Carcinoma - Pipeline by Xspray Pharma AB, H2 2017 150
Hepatocellular Carcinoma - Pipeline by Yooyoung Pharm Co Ltd, H2 2017 150
Hepatocellular Carcinoma - Pipeline by Zhejiang Conba Pharmaceutical Co Ltd, H2 2017 151
Hepatocellular Carcinoma - Dormant Projects, H2 2017 1095
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..1), H2 2017 1096
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..2), H2 2017 1097
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..3), H2 2017 1098
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..4), H2 2017 1099
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..5), H2 2017 1100
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..6), H2 2017 1101
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd..7), H2 2017 1102
Hepatocellular Carcinoma - Discontinued Products, H2 2017 1103
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd..1), H2 2017 1104
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd..2), H2 2017 1105

List of Figures

Number of Products under Development for Hepatocellular Carcinoma, H2 2017 37
Number of Products under Development by Companies, H2 2017 38
Number of Products under Development by Universities/Institutes, H2 2017 48
Number of Products by Top 10 Targets, H2 2017 69
Number of Products by Stage and Top 10 Targets, H2 2017 69
Number of Products by Top 10 Mechanism of Actions, H2 2017 78
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 78
Number of Products by Top 10 Routes of Administration, H2 2017 87
Number of Products by Stage and Top 10 Routes of Administration, H2 2017 87
Number of Products by Top 10 Molecule Types, H2 2017 89
Number of Products by Stage and Top 10 Molecule Types, H2 2017 89

  • Global Breast Cancer Monoclonal Antibodies Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 153
    Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Scope of the Report: This report studies the Breast Cancer Monoclonal Antibodies market status and outlook of Glo......
  • Global Immuno-Oncology Market Growth (Status and Outlook) 2018-2023
    Published: 19-Oct-2018        Price: US 3660 Onwards        Pages: 153
    Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers. Over the next five years, LPI(LP Information) projects that Immuno-Oncology will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017. In this report, LP Information studies the present scenario (with the base year bei......
  • Global Bladder Cancer Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 115
    The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells. Scope of the Report: This report studies the Bladder Cancer Therape......
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 218
    Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2018, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape. Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scal......
  • Essential Thrombocythemia - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 94
    Essential Thrombocythemia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H2 2018, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape. Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essen......
  • Pheochromocytoma - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 94
    Pheochromocytoma - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H2 2018, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness o......
  • Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 116
    Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) (Oncology) pipeline landscape. Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal corte......
  • Rhabdomyosarcoma - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 307
    Rhabdomyosarcoma - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2018, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape. Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the......
  • Uveal Melanoma - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 235
    Uveal Melanoma - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma - Pipeline Review, H2 2018, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape. Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these c......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs